Hadassah Medical CenterHadassah Medical Center
   Home    About    International Patient    Contact 
Home > Physicians, Dentists, Investigators

Dr. Marc Wygoda, MD

 

Updated September 2007

 

 

Chief, Radiotherapy Unit

Department of Oncology

Hadassah University Hospital

Jerusalem, Israel

Tel: 972-2-6778289

E-mail: mwygoda@hadassah.org.il

 

 

 

Work History

 

June 1999 – Present - Chief, Radiotherapy Unit

Department of Oncology, Hadassah University Hospital, Jerusalem, Israel

 

January 1992 - July 1995

August 1997 -  June 1999 - Attending Physician, Department of Oncology, Hadassah University Hospital, Jerusalem, Israel

 

August 1995 - July 1997 – Fellow, Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, US

Clinical work: - 3-Dimensional Conformal Radiotherapy

Research:  - Gene therapy - Radiosensitization mechanisms

 

Education

 

1990: Course on Oncogenes and Growth Factors, British Council, London, England.

 

1986 -1991: Residency in Oncology, Hadassah University Hospital.

 

1974- 1985: Medical School and MD Certification. Faculty of Medicine, University Louis Pasteur, Strasbourg, France.

 

1971-1974: Baccalaureat C, French High School Graduation in Science. Academie de Strasbourg, France.

 

Academic Appointments

 

1990: Clinical Instructor in Oncologym Hadassah University Hospital.

 

Awards

 

1992: Arthur E. Zemmel Award

 

Membership In Professional Societies

 

§         American Association for Therapeutic Radiology and Oncology

§         European Society for Therapeutic Radiology and Oncology

§         Israel Medical Association

§         Israel Association of Oncology

§         President of the Israeli Radiotherapy Forum since May 2007

 

List of Publications

 

Articles

 

1. Pfeffer M.R, Wygoda M, Siegal T.: Leptomeningeal metastases: treatment results in 98 consecutive patients.  Israel Journal Medical Sciences, vol. 24: 9-10, p.611-618, 1988,

 

2. Gez E, Wygoda M, Nussbaum B, Figer A, Igal-Gil R, Inbar M.: Surveillance in patients with stage I testicular non-seminomatous germ cell tumors.  Cancer Investigation, 11 (1): 10-14, 1993

 

3. Roisman I, Barak V, Libson E, Wygoda M, Neuman A, Sherman Y, Durst AL.:  Fat necrosis below musculocutaneous flap mimicking carcinoma of the breast.  Annals of Plastic Surgery, 26(5):479-82, 1991.

 

4. Bitan M, Mohsen M, Levi E, Wygoda M, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishai-Michaeli R, Bar-Shavit R,  Vlodavski I.: Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.  Israel Journal Medical Sciences, 31(2-3):106-118, 1995.

 

5. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Wygoda M,

Ishai-Michaeli R, Peretz T.

Inhibition of tumor metastasis by heparanase inhibiting species of heparin.

Invasion and Metastasis, 14:290-302, 1994-1995.

 

6. Wygoda M, Peretz T.:  Cytotoxic chemotherapy of prostatic carcinoma.  BAMA, 8: 57-63, 1995.

 

7. Sichel JY, Wygoda M, Osin P, Elidan J.:  Fibrosarcoma of the thyroid in a man exposed to fallout from the Chernobyl accident.  Ann. Otol. Rhinol. Laryngol, 105: 832-834, 1996.

 

8. Wygoda M.R, Wilson M.R, Davis M.A, Trosko J.E, Rehemtulla A, Lawrence T.S.: Protection of Herpes Simplex Virus Thymidine Kinase-transduced cells from Ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan Effect.  Cancer Research, 57:1699-1703, 1997.

 

9. Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, Tochner ZA.: Kindler syndrome complicated by squamous cell carcinoma of the hard palate: successful treatment with high dose radiation therapy and granulocyte-macrophage colony-stimulating factor.  Br J Dermatology, 144(6); 1284-86, 2001

 

10. Baider L, Ever-Hadani P, Goldzweig G, Wygoda MR, Perets T.:  Is perceived family support a relevant variable in psychological distress?. A sample of prostate and breast cancer couples.  J Psychosom Res, 55(5):453-60, 2003

 

11. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben-Sasson SA.:  Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts.  Cancer Res. Feb 1;64(3): 1058-66, 2004

 

12. Shoshan Y, Wygoda M, Umansky F.:  Stereotactic radiosurgery and fractionated stereotactic radiotherapy: background,definitions, applications. Isr Med Assoc J Sep;7(9):597-9, 2005

 

13. Meir K, Wygoda M, Reichman O, Gofrit ON, Pizov G.:  Puerperal renal rhabdomyosarcoma: case report and review of the literature. Urol Oncol. Jan-Feb;24(1):40-3, 2006

 

14. Belkacemi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N.: Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 2006 Dec 1

 

15. Grenader T, Shavit L, Lossos A, Pizov G, Wygoda M.:  Brain metastases: a rare initial presentation of prostate cancer. Int Urol Nephrol.;39(2):537-9, 2007

 

16. Yerushalmi R, Levi I, Wygoda M, Ifergane G, Wirguin I.:  Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease? J Peripher Nerv Syst. Jun;12(2):139-41, 2007

 




Dr. Marc Wygoda



            
     
 


         Powered by